When to Stop.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
07 2019
Historique:
pubmed: 11 6 2019
medline: 20 2 2020
entrez: 11 6 2019
Statut: ppublish

Résumé

Background and Purpose- Substantial proportion of patients who achieve successful recanalization of acute ischemic stroke due to large vessel occlusion do not achieve good functional outcome. We aim to analyze the effect of number of thrombectomy device passes and degree of the recanalization (by modified Thrombolysis in Cerebral Infarction) on the clinical and functional outcome. Methods- Five hundred forty-two consecutive patients underwent mechanical thrombectomy for large vessel occlusion in the anterior circulation at a single tertiary stroke center. Baseline characteristics, number of passes, recanalization degree, clinical outcome at 24 hours (measured by National Institutes of Health Scale score), and functional outcome (measured by modified Rankin Scale at 90 days) were registered. Multivariate analysis was performed to determine the association of number of passes and degree of recanalization with dramatical clinical recovery (final National Institutes of Health Scale score ≤2 or decrease in 8 or more National Institutes of Health Scale score points in 24 hours) and good functional outcome (modified Rankin Scale score ≤2 at 90 days). Results- Four hundred fifty-nine patients (84%) achieved successful recanalization (modified Thrombolysis in Cerebral Infarction 2B-3), 213 (39%) of them after first device pass. In the multivariate analysis, first-pass recanalization and modified Thrombolysis in Cerebral Infarction 3 were independent predictors of good functional outcome (odds ratio, 2.5; 95% CI, 1.4-4.5; P=0.002 and odds ratio, 2.6 CI; 1.5-4.7; P=0.001, respectively) and dramatical clinical recovery (odds ratio, 1.8; 95% CI, 1.1-3; P=0.032 and odds ratio, 2.9; 95% CI, 1.7-5.1; P<0.001, respectively). Rate of recanalization declined after each pass 39% (213/542), 35% (113/310), 33% (63/190), and 24% (26/154) for passes 1 to 4, respectively and 28% (45/158) for every attempt above 4 passes ( P<0.001). In patients who achieved recanalization, a linear association between number of passes and good functional outcome was observed: 1 pass (58.6%), 2 passes (50.5%), 3 passes (48.4%), 4 passes (38.5%), or 5 or more passes (25.6%; P<0.001) as compared with patients who did not achieve recanalization (16.9%). Conclusions- High number of device passes and less degree of recanalization are associated with worse outcome in patients with acute ischemic stroke secondary to large vessel occlusion. Future studies should investigate the optimal number of passes that should be attempted in patients without substantial recanalization.

Identifiants

pubmed: 31177974
doi: 10.1161/STROKEAHA.119.025088
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1781-1788

Commentaires et corrections

Type : ErratumIn

Auteurs

Álvaro García-Tornel (Á)

From the Stroke Unit, Department of Neurology (A.G.-T., M. Requena, M. Rubiera, M.M., J.P., D.R.-L., M.D., J.J., N.R.-V., S.B., M.O.-G., C.A.M., M. Ribo), Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

Manuel Requena (M)

From the Stroke Unit, Department of Neurology (A.G.-T., M. Requena, M. Rubiera, M.M., J.P., D.R.-L., M.D., J.J., N.R.-V., S.B., M.O.-G., C.A.M., M. Ribo), Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

Marta Rubiera (M)

From the Stroke Unit, Department of Neurology (A.G.-T., M. Requena, M. Rubiera, M.M., J.P., D.R.-L., M.D., J.J., N.R.-V., S.B., M.O.-G., C.A.M., M. Ribo), Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

Marian Muchada (M)

From the Stroke Unit, Department of Neurology (A.G.-T., M. Requena, M. Rubiera, M.M., J.P., D.R.-L., M.D., J.J., N.R.-V., S.B., M.O.-G., C.A.M., M. Ribo), Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

Jorge Pagola (J)

From the Stroke Unit, Department of Neurology (A.G.-T., M. Requena, M. Rubiera, M.M., J.P., D.R.-L., M.D., J.J., N.R.-V., S.B., M.O.-G., C.A.M., M. Ribo), Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

David Rodriguez-Luna (D)

From the Stroke Unit, Department of Neurology (A.G.-T., M. Requena, M. Rubiera, M.M., J.P., D.R.-L., M.D., J.J., N.R.-V., S.B., M.O.-G., C.A.M., M. Ribo), Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

Matias Deck (M)

From the Stroke Unit, Department of Neurology (A.G.-T., M. Requena, M. Rubiera, M.M., J.P., D.R.-L., M.D., J.J., N.R.-V., S.B., M.O.-G., C.A.M., M. Ribo), Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

Jesus Juega (J)

From the Stroke Unit, Department of Neurology (A.G.-T., M. Requena, M. Rubiera, M.M., J.P., D.R.-L., M.D., J.J., N.R.-V., S.B., M.O.-G., C.A.M., M. Ribo), Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

Noelia Rodríguez-Villatoro (N)

From the Stroke Unit, Department of Neurology (A.G.-T., M. Requena, M. Rubiera, M.M., J.P., D.R.-L., M.D., J.J., N.R.-V., S.B., M.O.-G., C.A.M., M. Ribo), Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

Sandra Boned (S)

From the Stroke Unit, Department of Neurology (A.G.-T., M. Requena, M. Rubiera, M.M., J.P., D.R.-L., M.D., J.J., N.R.-V., S.B., M.O.-G., C.A.M., M. Ribo), Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

Marta Olivé-Gadea (M)

From the Stroke Unit, Department of Neurology (A.G.-T., M. Requena, M. Rubiera, M.M., J.P., D.R.-L., M.D., J.J., N.R.-V., S.B., M.O.-G., C.A.M., M. Ribo), Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

Alejandro Tomasello (A)

Department of Neurorradiology (A.T., D.H.), Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

David Hernández (D)

Department of Neurorradiology (A.T., D.H.), Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

Carlos A Molina (CA)

From the Stroke Unit, Department of Neurology (A.G.-T., M. Requena, M. Rubiera, M.M., J.P., D.R.-L., M.D., J.J., N.R.-V., S.B., M.O.-G., C.A.M., M. Ribo), Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

Marc Ribo (M)

From the Stroke Unit, Department of Neurology (A.G.-T., M. Requena, M. Rubiera, M.M., J.P., D.R.-L., M.D., J.J., N.R.-V., S.B., M.O.-G., C.A.M., M. Ribo), Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH